4th Quarter - Amendment
BRIDGEBIO PHARMA, INC. for BRIDGEBIO PHARMA, INC.
Client
Income
—
Expenses
$330,000
Expense method
A: Lobbying Disclosure Act definitions
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 20, 2025 | $320,000 | Replaced |
| 4th Quarter - Amendment (this page) | Jul 17, 2026 | $330,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Creating Hope Reauthorization Act of 2024 - H.R. 7384 Give Kids a Chance Act of 2024 - H.R. 3433 Creating Hope Reauthorization Act of 2024 - S. 4583 March-in/Bayh-Dole Act Orphan drug policies Scientific EXPERT Act of 2024 - H.R.9979 H.R.9979 - Scientific EXPERT Act of 2024 H.R.10545 - American Relief Act, 2025
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL CALVO New | Rep. Taylor (NC-11) Intern, Leg. Correspondent, Leg. Asst. Rep. McHenry (NC-10) Policy Advisor Rep. Gingrey (GA-11) Senior Leg. Asst., Senior Policy Advisor, Leg. Director, Deputy Chief of Staff Rep. Hice (GA-10) Leg. Director |
| AMANDA MALAKOFF | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.